Colorado Retina Associates | Lakewood, CO

Research site

(Unclaimed)

Location

255 South Routt Street Suite 200, Lakewood, Colorado, United States of America

Site insights

Top conditions

Top treatments

ABP 938

EYE103

Zimura

Axitinib

AU-011

EYP-1901

Aflibercept

Pegcetacoplan

BI 771716

Eylea®

Parent organization

This site is a part of Colorado Retina Associates

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 11 total trials

4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling

Neovascular (Wet) Age-Related Macular Degeneration

Biological: 4D-150 IVT

Biological: Aflibercept IVT

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling

Wet Age Related Macular Degeneration

wAMD

Drug: Aflibercept (2.0 mg)

Drug: EYP-1901

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling

Indeterminate Lesions

Ocular Melanoma

Device: Suprachoroidal Microinjector

Drug: Bel-sar

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy (VERDANT)

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Enrolling

Macular Degeneration, Age-related

Geographic Atrophy

Drug: Pegcetacoplan

Drug: Sham comparator to BI 771716

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Biological: Aflibercept (EYLEA®)

Genetic: ABBV-RGX-314 Dose 2